Free Trial
→ Tesla. SolarCity. Twitter. This $4 stock is next. (From Behind the Markets) (Ad)tc pixel
NASDAQ:PTIX

Atrinsic Q2 2024 Earnings Report

Atrinsic logo
$0.53 +0.03 (+5.28%)
As of 12:35 PM Eastern
ProfileEarnings HistoryForecast

Atrinsic EPS Results

Actual EPS
-$5.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Atrinsic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atrinsic Announcement Details

Quarter
Q2 2024
Date
8/14/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Atrinsic Earnings Headlines

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
July 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/30/3124067/0/en/protagenic-therapeutics-announces-grant-of-new-patent-in-japan-for-its-modified-stilbenoid-program-drug-candidates.html
Protagenic Therapeutics, Inc. (PTIX) - Yahoo Finance
June 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/PTIX/news/
How to claim a stake in SpaceX before the June 12 IPO
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in before the IPO. Jeff Brown, who identified Bitcoin, Tesla, and Nvidia before gains as high as 52,400%, 2,150%, and 32,000% respectively, is sharing the details on how to claim a stake in Elon Musk's company before it hits public markets.tc pixel
June 8 at 1:00 AM  |  Brownstone Research (Ad)
Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail Frenzy
May 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/protagenic-phytanix-merge-in-all-stock-move-sparking-retail-frenzy/ar-AA1FJicU
Protagenic Therapeutics swaps warrants for shares
May 21, 2025  |  uk.investing.comhttps://uk.investing.com/news/sec-filings/protagenic-therapeutics-swaps-warrants-for-shares-93CH-4095880
Protagenic Therapeutics Shares Double After Buyout Offer From Phytanix Bio
May 20, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/protagenic-therapeutics-shares-double-after-buyout-offer-from-phytanix-bio-4ee93d1e
See More Atrinsic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atrinsic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atrinsic and other key companies, straight to your email.

About Atrinsic

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

View Atrinsic Profile
Earnings Tools